Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Agomelatine - Servier

Drug Profile

Agomelatine - Servier

Alternative Names: AGO-178; AGO178C; Alodil; Melitor; S-20098; S-20098-F55; Thymanax; Valdoxan; Vestin

Latest Information Update: 17 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Servier
  • Developer Novartis; Servier
  • Class Acetamides; Antidepressants; Anxiolytics; Behavioural disorder therapies; Hypnosedatives; Sleep disorder therapies; Small molecules
  • Mechanism of Action Melatonin MT1 receptor agonists; Melatonin MT2 receptor agonists; Serotonin 2C receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Suspended Generalised anxiety disorder
  • No development reported Obsessive-compulsive disorders
  • Discontinued Sleep disorders

Most Recent Events

  • 11 Aug 2017 Suspended - Phase-II for Generalised anxiety disorder (In adolescents, In children) in Poland, Romania, Estonia, Hungary, Sweden, Finland (PO,Tablet) (Servier email communication, August 2017)
  • 11 Aug 2017 Suspended - Phase-II for Generalised anxiety disorder in South Africa (PO, capsule) (Servier email communication, August 2017)
  • 11 Aug 2017 Suspended - Phase-III for Generalised anxiety disorder in Canada, Poland, Russia, Czech Republic, Australia, Germany, Hungary, Slovakia, France, Ukraine, Finland, Argentina (PO,Capsule) (Servier email communication, August 2017)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top